DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Miyoshi muscular dystrophy 1 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMiyoshi muscular dystrophy 1 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for miyoshi muscular dystrophy 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 1965 trial of anabolic steroids in 21 patients with muscular dystrophy, 17 of them boys with the pseudohypertrophic form, found that one year after treatment all patients were significantly worse. None showed any change that could be interpreted as improvement, and five boys lost the ability to walk. Physicians at eight other centres, with experience in the same therapy in approximately 300 patients, reported no evidence of objective benefit. A 2012 review of pharmacological therapies for muscular dystrophies noted that the field continues to advance, with research exploring mutation-specific strategies and pharmacological approaches that might ameliorate disease pathology, but it did not report any specific results for Miyoshi muscular dystrophy.
A 2025 scoping review of treatments for adult type 1 myotonic dystrophy found only 86 studies, two-thirds of which had fewer than 30 participants. The main treatment targets were muscle symptoms (50%), respiratory issues (15.1%), central nervous system problems (12.7%), and cardiac conduction disorders (10.5%). Most treatments were pharmacotherapies (43%), followed by physical training (15.1%), non-invasive ventilation (11.5%), and cardiac resynchronisation therapy (10.5%). The distribution of treatment targets did not match patient-reported symptom burden well, and outcome measures were varied and not standardised. A 2023 chapter on drug repositioning in muscular dystrophies stated that there is no cure for these disorders, that effective treatments have yet to be developed despite knowledge of their genetic origins, and that drug repurposing is an accelerated method that relies on existing safety and pharmacokinetic data.
No abstract in this set reports a trial or any data specific to Miyoshi muscular dystrophy 1. The evidence for pharmacological intervention in muscular dystrophies more broadly is either negative, as with the 1965 steroid trial, or limited to small, poorly standardised studies that do not address patient priorities. What is still missing is any clinical trial data for Miyoshi muscular dystrophy 1 itself, adequate funding for adequately powered studies, and a trial design that uses standardised outcome measures aligned with what patients report matters to them.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Neurology · 2012 · 24 citations
Pharmacological therapies for muscular dystrophies
AbstractPURPOSE OF REVIEW: The study reviews recent advances in pharmacological management of muscular dystrophies. Similarities and differences among the pathophysiology of different forms of muscular dystrophy lead to a broad array of approaches to provide new treatments. RECENT FINDINGS: In this review, we include only those muscular dystrophies for which advances have been published in the past year. This represents the 'advancing edge' of a large body of research over more than 20 years. This runs the gamut of new discoveries in symptomatic management to mutation-specific strategies that attempt to correct the root cause of the disorder. SUMMARY: The field of pharmacological therapies for the muscular dystrophies continues to steadily advance. It is encouraging that research into new therapies is increasingly exploring pharmacological strategies with the potential to ameliorate disease pathology to a clinically significant degree.
New England Journal of Medicine · 1967 · 20 citations
The Significance of Decreased Body Potassium Concentrations in Patients with Muscular Dystrophy and Nondystrophic Relatives
AbstractPATIENTS with muscular dystrophy and also some of their nondystrophic relatives, particularly mothers and female siblings, have diminished total-body potassium concentrations.1 , 2 The diminution of body potassium in these patients appears to correlate with the severity of muscle involvement. On the other hand, the reduced body potassium concentrations observed in some nondystrophic relatives have suggested a biochemical trait with possible genetic implications.There are several possible explanations for such diminished levels of body potassium. It would be logical to assume that the dystrophic patient's loss of body potassium is related to the gradual replacement of normal muscle tissue by potassium-poor fat . . .
ANABOLIC STEROIDS IN THE MANAGEMENT OF MUSCULAR DYSTROPHY
AbstractA group of 21 patients with muscular dystrophy, 17 of them boys with the pseudohypertrophic form, were treated with a regimen including the use of an anabolic steroid, digitoxin, and physical exercise. This program had previously been reported to be efficacious. One year after the initiation of treatment all patients in the present study were significantly worse. None showed any change which could be interpreted as representing improvement. Five boys displayed rather rapid progression of the disease leading to loss of ambulation. Physicians at eight other centers, with experience in trials of identical therapy in approximately 300 patients, report no evidence of any objective benefit from the use of this steroid therapy in muscular dystrophy.
Journal of the Neurological Sciences · 2025 · 2 citations · open access
Treatments and therapies for symptoms and clinical manifestations of adult type 1 myotonic dystrophy: A scoping review
AbstractMyotonic Dystrophy is the most common adult-onset muscular dystrophy, with a broad, multi-systemic presentation. There is no cure, so quality-of-life improvements rely on treatment of symptoms and clinical manifestations. This review aimed to synthesize primary research evaluating treatments or therapies for symptoms and clinical manifestations of adult type 1 Myotonic Dystrophy and map targets against patient-reported symptom burden. Embase, MEDLINE, Web of Science, CINAHL, CENTRAL, and PsycINFO were searched for relevant studies published to 16th of October 2024. Two independent reviewers screened title and abstract, then full-text records for eligibility and conflicts were settled by group discussion. Study information was extracted, and treatment targets were mapped against patient-reported symptom burden as reported by Hagerman et al. The literature was limited to only 86 studies; 2/3 conducted in cohorts of <30 participants. Main target symptoms were muscle (50 %), respiratory (15.1 %), central nervous system (12.7 %) and cardiac conduction disorders (10.5 %). Most treatments were pharmacotherapies (43 %), followed by physical training (15.1 %), Non-invasive Ventilation (11.5 %), and Cardiac Resynchronization Therapy (10.5 %). The distribution of treatment targets was poorly representative of patient-reported symptoms. Outcome measures, clinical and patient-reported, were varied and utilized without standardization within treatment categories. These findings emphasize the need for evidence-based clinical management targeting patient priorities to produce quality-of-life improvements.
IntechOpen eBooks · 2023 · 0 citations · open access
The Potential Benefits of Drug-Repositioning in Muscular Dystrophies
AbstractMuscular dystrophies (MDs) are a complex group of rare neuromuscular disorders caused by genetic mutations that progressively weaken the muscles, resulting in an increasing level of disability. The underlying cause of these conditions consists of mutations in the genes in charge of a person’s muscle composition and functionality. MD has no cure, but medications and therapy can help control symptoms and slow the disease’s progression. Effective treatments have yet to be developed, despite the identification of the genetic origins and a thorough knowledge of the pathophysiological alterations that these illnesses induce. In this scenario, there is an urgent need for novel therapeutic options for these severe illnesses, and drug repositioning might be one feasible answer. In other words, drug repositioning/repurposing is an accelerated method of developing novel pharmaceuticals since the new indication is based on previously accessible safety, pharmacokinetic, and manufacturing data. This is particularly crucial for individuals with life-threatening illnesses such as MDs, who cannot wait for a conventional medication development cycle. This chapter aims to review the challenges and opportunities of drug-repositioning in a variety of MDs to establish novel treatment approaches for these incurable diseases.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
